venous%20thromboembolism%20-%20management
VENOUS THROMBOEMBOLISM - MANAGEMENT
Deep vein thrombosis is a frequent manifestation of venous thromboembolism in which there is a blood clot blocking a deep vein.
Clinical findings are important to the diagnosis of deep vein thrombosis but are poor predictors of the presence or severity of thrombosis.
Pulmonary embolism is the blockage of the blood vessels in the lungs usually due to blood clots from the veins, especially veins in the legs and pelvis.
Dyspnea, pleuritic chest pain, syncope and tachypnea occur in most cases of pulmonary embolism.
Massive pulmonary embolism has the prime symptom of dyspnea and systemic arterial hypotension that requires pressor support is the predominant sign.

Differential Diagnosis

  • Since pain and swelling are common presenting complaints, DVT must be differentiated from other causes including the following:
    • Muscle strain, rupture or tear
    • Leg swelling in paralyzed leg
    • Lymphangitis, lymphedema
    • Cellulitis
    • Ruptured popliteal cyst (Baker’s cyst)
    • Venous insufficiency
    • Superficial thrombophlebitis
Massive Pulmonary Embolism
  • Cardiogenic shock
  • Cardiac tamponade
  • Aortic dissection
  • Pneumonia
  • Massive myocardial infarction
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
24 Dec 2017
Losartan at 50 mg is effective in reducing blood pressure in patients with postdialysis euvolemic hypertension, a recent study has shown.
29 Dec 2017
Preoperative hyponatraemia and higher body mass index (BMI) before surgery increase the risk of postoperative stress-related cardiomyopathy (SRC), according to a recent study.
24 Dec 2017
Cardiovascular (CV) diseases or CV risk factors account for the reduced quality of life (QOL) in diabetics compared with nondiabetics, a recent study has found.
24 Dec 2017
The CENTERA transcatheter heart valve (THV) has been proven safe and effective in high-surgical-risk patients with severe symptomatic aortic stenosis at 30 days, resulting in low mortality, significant improvements in haemodynamic outcomes, and low incidence of adverse events, according to a study.